Table 2.

Univariate analysis for overall survival and distant progression-free survival

		No. of patients*	5-year OS (%)	p Value	5-year DPFS (%)	p Value
Race
	White	119	30	0.05	20	<.001
	Black	32	17		0
	Other	21	38		27
ECOG Performance Status
	0-1	126	31	0.01	18	0.002
	>1	29	11		5
Menopausal status
	Post	100	34	0.44	21	0.79
	Pre	69	27		14
Hormone receptor
	Pos	89	31	0.12	15	0.81
	Neg	77	25		18
HER2 receptor
	Pos	45	44	0.002	25	<.001
	Neg	117	20		11
Grade
	1	3	67	0.73	33	0.47
	2	38	24		15
	3	120	28		17
LVSI
	Yes	78	27	<.001	16	<.001
	No	39	52		40
	Unknown	55
Histology
	Ductal	136	30	0.92	18	0.88
	Lobular	13	42		19
	Mixed	14	19		9
Systemic therapy
	Chemo only	117	28	0.63	17	0.42
	Chemo+endocrine	55	29		8
Response to systemic therapy
	Non-responders	69	13	<.0001	8	<.0001
	Responders	98	41		24
Locoregional therapy
	None	75	9	<.0001	0	<.0001
	Radiotherapy alone	18	14		15
	Surgery alone	11	25		18
	Surgery+radiotherapy	68	50		32
Surgery
	Yes	79	47	<.0001	30	<.0001
	No	93	10		3
Surgical intent
	Curative	47	49	0.66	35	0.56
	Local control	32	44		24
Margin status
	Negative	60	48	0.92	33	0.38
	Positive	7	47		42
	Close	8	40		25
pCR
	Yes	12	60	<.001	61	<.001
	No	67	26		13
# distant disease sites
	1	94	34	0.05	24	<.001
	>1	78	18		6

^*Patients with unknown data were excluded, thus totals may vary

Abbreviations: OS, overall survival; DPFS, distant progression-free survival; ECOG, Eastern Cooperative Oncology Group; LVSI, lymphovascular space invasion; pCR pathologic complete response